Department of Colorectal Disease, Intestinal Microenvironment Treatment Center, General Surgery of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Tongji University School of Medicine, Shanghai, 200072, China.
BMC Microbiol. 2024 May 9;24(1):160. doi: 10.1186/s12866-024-03261-0.
Antibiotic-associated diarrhea (AAD) refers to symptoms of diarrhea that cannot be explained by other causes after the use of antibiotics. AAD is thought to be caused by a disruption of intestinal ecology due to antibiotics. Fecal Microbiota Transplantation (FMT) is a treatment method that involves transferring microbial communities from the feces of healthy individuals into the patient's gut.
We selected 23 AAD patients who received FMT treatment in our department. Before FMT, we documented patients' bowel movement frequency, abdominal symptoms, routine blood tests, and inflammatory markers, and collected fecal samples for 16S rRNA sequencing to observe changes in the intestinal microbiota. Patients' treatment outcomes were followed up 1 month and 3 months after FMT.
Out of the 23 AAD patients, 19 showed a clinical response to FMT with alleviation of abdominal symptoms. Among them, 82.61% (19/23) experienced relief from diarrhea, 65% (13/20) from abdominal pain, 77.78% (14/18) from abdominal distension, and 57.14% (4/7) from bloody stools within 1 month after FMT. Inflammatory markers IL-8 and CRP significantly decreased after FMT, but there were no noticeable changes in WBC, IL-6, and TNF-α before and after transplantation. After FMT, the abundance of Bacteroides and Faecalibacterium increased in patients' fecal samples, while the abundance of Escherichia-Shigella and Veillonella decreased.
FMT has a certain therapeutic effect on AAD, and can alleviate abdominal symptoms and change the intestinal microbiota of patients.
抗生素相关性腹泻（AAD）是指在使用抗生素后，无法用其他原因解释的腹泻症状。AAD 被认为是由于抗生素导致肠道生态失调引起的。粪便微生物群移植（FMT）是一种治疗方法，涉及将健康个体粪便中的微生物群落转移到患者的肠道中。
我们选择了在我科接受 FMT 治疗的 23 例 AAD 患者。在 FMT 之前，我们记录了患者的排便频率、腹部症状、常规血液检查和炎症标志物，并收集粪便样本进行 16S rRNA 测序，以观察肠道微生物群的变化。患者的治疗结果在 FMT 后 1 个月和 3 个月进行随访。
在 23 例 AAD 患者中，有 19 例对 FMT 有临床反应，腹部症状缓解。其中，82.61%（19/23）腹泻缓解，65%（13/20）腹痛缓解，77.78%（14/18）腹胀缓解，57.14%（4/7）血便缓解，FMT 后 1 个月内。FMT 后，IL-8 和 CRP 等炎症标志物显著降低，但 WBC、IL-6 和 TNF-α 在移植前后无明显变化。FMT 后，患者粪便样本中拟杆菌和粪杆菌丰度增加，而大肠埃希菌-志贺菌和韦荣球菌丰度降低。
FMT 对 AAD 有一定的治疗作用，能缓解腹部症状，改变患者的肠道微生物群。
